|
|
 Previous Article | Table of Contents | Next Article 
Interferon-alpha in mixed cryoglobulinemia patients: a randomized,
crossover-controlled trial
C Ferri, E Marzo, G Longombardo, F Lombardini, L La Civita, R Vanacore, AM Liberati, R Gerli, F Greco and A Moretti
Rheumatology Unit, University of Pisa, Italy.
The effects of interferon-alpha (IFN-alpha) on clinical and serologic
manifestations of mixed cryoglobulinemia (MC) were investigated by
randomized, crossover-controlled trial in 26 patients. The trial alternated
6 months with and 6 months without IFN-alpha therapy (2 x 10(6) IU daily
for a month, then every other day for 5 months). In 22 patients,
pretreatment steroid dosage remained unchanged during the study. Six
patients dropped out (three because of side effects), whereas another 20
patients experienced a significant improvement of purpura (P < .02) and
serum transaminases (P < .005) during IFN-alpha treatment. The presence
of clinical improvement was supported by the outcome measurements of
several immunologic parameters. In particular, serum cryoglobulins were
significantly reduced (P < .04) during IFN- alpha therapy. A rebound
phenomenon of clinical and serologic parameters was observed after
IFN-alpha discontinuation. In addition, no variations were recorded during
6 months without therapy. Hepatitis C virus (HCV) RNA was detected in 91%
(20/22) of our MC patients; in 2/13 cases HCV RNA was no longer detectable
in serum samples after IFN- alpha therapy. Thus, IFN-alpha could be
considered as treatment for MC in patients with HCV seropositivity.
Volume 81,
Issue 5,
pp. 1132-1136,
03/01/1993
Copyright © 1993 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
C. Briani, L. Chemello, G. Zara, M. Ermani, E. Bernardinello, S. Ruggero, E. Toffanin, A. Gatta, L. Battistin, and L. Cavalletto
Peripheral neurotoxicity of pegylated interferon alpha: a prospective study in patients with HCV.
Neurology,
September 12, 2006;
67(5):
781 - 785.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Dimopoulos, R. A. Kyle, A. Anagnostopoulos, and S. P. Treon
Diagnosis and Management of Waldenstrom's Macroglobulinemia
J. Clin. Oncol.,
March 1, 2005;
23(7):
1564 - 1577.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Ramos-Casals, O. Trejo, M. Garcia-Carrasco, and J. Font
Therapeutic management of extrahepatic manifestations in patients with chronic hepatitis C virus infection
Rheumatology,
July 1, 2003;
42(7):
818 - 828.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Sansonno, V. De Re, G. Lauletta, F. A. Tucci, M. Boiocchi, and F. Dammacco
Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20
Blood,
May 15, 2003;
101(10):
3818 - 3826.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. A. Sabry, M. A. Sobh, H. A. Sheaashaa, G. Kudesia, G. Wild, S. Fox, B. E. Wagner, W. L. Irving, A. Grabowska, and A. M. El-Nahas
Effect of combination therapy (ribavirin and interferon) in HCV-related glomerulopathy
Nephrol. Dial. Transplant.,
November 1, 2002;
17(11):
1924 - 1930.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J Thiel, T Peters, A Mas Marques, B Rosler, H H Peter, and S M Weiner
Kinetics of hepatitis C (HCV) viraemia and quasispecies during treatment of HCV associated cryoglobulinaemia with pulse cyclophosphamide
Ann Rheum Dis,
September 1, 2002;
61(9):
838 - 841.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Rieu, P. Cohen, M.-H. Andre, L. Mouthon, P. Godmer, B. Jarrousse, F. Lhote, F. Ferriere, P. Deny, P. Buchet, et al.
Characteristics and outcome of 49 patients with symptomatic cryoglobulinaemia
Rheumatology,
March 1, 2002;
41(3):
290 - 300.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P Lamprecht, F Moosig, A Gause, K Herlyn, E Csernok, H Hansen, and W L Gross
Immunological and clinical follow up of hepatitis C virus associated cryoglobulinaemic vasculitis
Ann Rheum Dis,
April 1, 2001;
60(4):
385 - 390.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Ramos-Casals, O. Trejo, M. Garcia-Carrasco, R. Cervera, and J. Font
Mixed cryoglobulinemia: new concepts
Lupus,
February 1, 2000;
9(2):
83 - 91.
[Abstract]
[PDF]
|
|
|
|
|
|
|
O M CROSBIE and G J M ALEXANDER
Cryoglobulinaemia in HCV infection: coming in from the cold
Gut,
July 1, 1999;
45(1):
8 - 9.
[Full Text]
|
|
|
|
|
|
|
P Cresta, L Musset, P Cacoub, L Frangeul, D Vitour, T Poynard, P Opolon, D-T Nguyen, F Golliot, J-C Piette, et al.
Response to interferon alpha treatment and disappearance of cryoglobulinaemia in patients infected by hepatitis C virus
Gut,
July 1, 1999;
45(1):
122 - 128.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C Ferri, L La Civita, G Longombardo, A L Zignego, and G Pasero
Mixed cryoglobulinaemia: a cross-road between autoimmune and lymphoproliferative disorders
Lupus,
May 1, 1998;
7(4):
275 - 279.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. Casato, V. Agnello, L. P. Pucillo, G. B. Knight, M. Leoni, S. Del Vecchio, C. Mazzilli, G. Antonelli, and L. Bonomo
Predictors of Long-Term Response to High-Dose Interferon Therapy in Type II Cryoglobulinemia Associated With Hepatitis C Virus Infection
Blood,
November 15, 1997;
90(10):
3865 - 3873.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Misiani, P. Bellavita, D. Fenili, O. Vicari, D. Marchesi, P. L. Sironi, P. Zilio, A. Vernocchi, M. Massazza, G. Vendramin, et al.
Interferon Alfa-2a Therapy in Cryoglobulinemia Associated with Hepatitis C Virus
N. Engl. J. Med.,
March 17, 1994;
330(11):
751 - 756.
[Abstract]
[Full Text]
|
|
|
|
|
